First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics

SAN ANTONIO, May 14, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (NASDAQ:VBIO), a clinical-stage immunotherapeutics company, today announced that its wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with LarmorBio, Inc. ("LarmorBio") for LarmorBio's BioScan-NMR™ platform, a next-generation nuclear magnetic resonance (NMR) system. Under the agreement, Velocity Bioworks will host the first commercial deployment of the BioScan-NMR platform, with installation and commissioning at the Company's San Antonio facility targeted for July 2026.